Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sigma-Aldrich Acquires ChemNavigator to Provide Researchers with Chemical Compound Selection and Procurement Services

Published: Friday, August 07, 2009
Last Updated: Friday, August 07, 2009
Bookmark and Share
Deal combines ChemNavigator's database of chemical compounds and cheminformatics tools with chemical services of Sigma-Aldrich.

Sigma-Aldrich has announced the acquisition of cheminformatics company,, Incorporated, a provider of discovery research informatics software tools used for design, selection and procurement of chemical compound libraries.

The acquisition links ChemNavigator's comprehensive suite of virtual screening and selection tools and searchable database of over 60 million compounds with Sigma-Aldrich's core strengths in chemical compound management, procurement and global distribution to accelerate discovery research programs.

Early in the drug discovery process, researchers work at the molecular level to perform structure activity relationship (SAR) studies, seeking molecular patterns that may exhibit enhanced biological activity against disease targets. This virtual discovery process typically leads to a selection of compounds that can be compiled into target libraries based upon the identified SARs and molecular designs. Target compounds must then be identified from among the millions of potentially available chemicals and procured for actual testing of their biological properties.

ChemNavigator provides medicinal, computational and synthetic chemists with a comprehensive set of virtual screening tools and products that allows them to channel their chemical designs toward sets of commercially available compounds.

The company's sourcing database, the iResearch Library™, contains millions of chemical products available for selection and purchase, ranging from drug-like compounds for testing in molecular screening to synthetic building blocks used in chemical synthesis.

The acquisition aligns the global procurement and distribution capabilities of Sigma-Aldrich's Discovery(CPR) service with ChemNavigator's front-end cheminformatics research tools. These newly combined capabilities will provide customers with the complete chemical discovery offer, from compound selection to delivery of custom packaged chemical building blocks and screening libraries ready for testing.

"ChemNavigator is well-recognized for its fast and efficient virtual discovery tools and for its extensive database of chemical compounds," said Dr. Ilya Koltover, Manager, Business Development, for Sigma-Aldrich. "This acquisition enables Sigma-Aldrich to provide the research community with an efficient, seamless discovery offer that extends from virtual selection to compound delivery."

"Joining Sigma-Aldrich brings ChemNavigator's database and cheminformatics tools to a broader scientific audience and will allow scientists to utilize the full potential of both companies' expertise to accelerate their research," said Scott Hutton, President and Chief Executive Officer, ChemNavigator.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich to Restructure Business into Three New Units
Sigma-Aldrich has provided the first details of a major restructuring that will align its organisation into three customer and market-focused business units.
Thursday, November 22, 2012
Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research
Sigma® Life Science to analyze plasma samples from FHS in researching novel biomarkers for cardiovascular disease.
Monday, August 09, 2010
Sigma-Aldrich Signs Exclusive Agreement with IsoSciences to Distribute Isotopically Labeled Bioactive Compounds
Under the terms of the agreement, IsoSciences will be the exclusive provider to Aldrich for their stable isotope products listed in the agreement for metabolic research.
Friday, September 12, 2008
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos